Analyse Humacyte, Inc. (HUMA) — Kairos Score 53/100

À propos de Humacyte, Inc.

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.

Informations clés

🕴️ Activité des initiés (90 jours)

1 transactions — 1 achats et 0 ventes déclarés par les dirigeants de Humacyte, Inc..

🏦 Hedge Funds

15 fonds institutionnels déclarent une position sur HUMA dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur HUMA.

• Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note
• Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.